# Cochrane

# Trusted evidence.

# Informed decisions.

# Better health.

# Cochrane Database of Systematic Reviews

# EUCTR 2019-003816-29 (Continued)

- Clinical remission (defined by CDAI &lt; 150) at week 52; endoscopic remission (defined by SES-CD = 2)
- Measures of inflammation: blood cell count, CRP level, fecal calprotectin at week 6 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7), and 52 (V8)
- Microbiota composition and diversity using 16s sequencing technology at week 6 (V3), 12 (V4), 24 (V5), 36 (V6), 48 (V7) and 52 (V8)

|Starting date|16 December 2019|
|---|---|
|Contact information|DRCI Hôpital Saint Louis 1 avenue Claude Vellefaux, 75010 Paris, France Telephone: 0140 27 57 27; email: carla.vandenabele@aphp.fr|
|Notes|Phase 3 trial|

# NCT01961492

# Study name

# Methods

RCT conducted in Finland

# Participants

# Inclusion criteria

- Ages 1–75 years
- Active UC (PUCAI 10–64)
- Ability to receive FMT via colonoscopy

# Exclusion criteria

- Severe UC (PUCAI &gt; 65)

# Interventions

# Experimental arm

- Single FMT via colonoscopy as adjunct therapy to standard medical treatment

# Control arm

- Standard medical treatment as recommended by ECCO guidelines for UC

# Outcomes

# Primary outcome

- UC activity as change from baseline in PUCAI at months 1, 3, 6, and 12

# Secondary outcomes

- Colonic inflammation as change from baseline in fecal calprotectin levels at months 1, 3, 6, and 12
- Colonic inflammation as Endoscopic Mayo score at months 3 and 12
- Adverse events within 1 year

# Starting date

# Contact information

# Notes

# Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.